Breakthrough trial aims to slash TB treatment time in half
NCT ID NCT06905522
Summary
This large, Phase 3 trial is testing a new, shorter combination of drugs to treat all types of active lung tuberculosis, including drug-resistant strains. The goal is to see if this 'pan-TB' regimen can safely cut treatment time from the current 4-6 months down to just 2-3 months while being just as effective. It will involve 610 adults with newly diagnosed TB to compare the new regimen against standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Chest Hospital of Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shenzhen Third People's Hospital
RECRUITINGShenzhen, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sixth People's Hospital of the Xinjiang Uygur Autonomous Region
RECRUITINGÜrümqi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.